GlassScriptPhysician profile
Yazen Joudeh
NPI 1134301773
$660,828.13
in general payments reported to CMS, 2019-2025
67 companies · $122K in 2025
The $122K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151K · 2020: $77K · 2021: $63K · 2022: $93K · 2023: $50K · 2024: $105K · 2025: $122K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $200K · Consulting Fee: $35K · Travel and Lodging: $27K · Food and Beverage: $16K · Education: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $200,108.39 |
| Consulting Fee | $34,532.50 |
| Travel and Lodging | $26,506.68 |
| Food and Beverage | $16,192.72 |
| Education | $168.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $285,521.94 | 2019-2025 | Zepbound, Mounjaro, Taltz |
| Novo Nordisk INC | $190,168.53 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $55,148.97 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amarin Pharma, INC. | $21,480.44 | 2019-2022 | |
| Amgen INC. | $19,576.13 | 2019-2025 | Tezspire, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $15,885.29 | 2019-2023 | Xarelto |
| Eli Lilly and Company | $15,199.85 | 2024-2025 | Zepbound, Mounjaro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13,881.66 | 2022-2025 | Caplyta |
| Pfizer INC. | $9,954.12 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $9,303.27 | 2021-2025 | |
| Allergan, INC. | $7,192.58 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $3,734.41 | 2019-2023 | Steglatro |
| Abbvie INC. | $1,859.17 | 2021-2025 | |
| Medicure Pharma INC. | $1,500.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $1,314.58 | 2020-2025 |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $948.44 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Teva Pharmaceuticals USA, INC. | $573.45 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $564.86 | 2019-2025 | Trulance, Xifaxan, Relistor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $511.72 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $503.80 | 2019-2023 | |
| Aimmune Therapeutics, INC. | $407.36 | 2024-2025 | Zenpep |
| Axsome Therapeutics, INC. | $377.07 | 2023-2025 | Auvelity, Sunosi, Symbravo |
| Upsher-Smith Laboratories LLC | $359.65 | 2019-2021 | |
| Ardelyx, INC. | $331.59 | 2023-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $321.73 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $313.49 | 2024-2025 | Voquezna |
| Abbott Laboratories | $247.80 | 2021-2023 | Freestyle Libre 3 |
| Antares Pharma, INC. | $225.61 | 2021-2025 | Xyosted |
| Currax Pharmaceuticals LLC | $207.82 | 2019-2024 | Onzetra Xsail, Contrave, Nexletol |
| Jazz Pharmaceuticals INC. | $192.93 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $174.23 | 2022 | |
| Redhill Biopharma INC. | $172.96 | 2020-2021 | |
| Radius Health, INC. | $169.05 | 2024-2025 | Tymlos |
| Astellas Pharma US INC | $159.70 | 2024-2025 | Veozah |
| Xeris Pharmaceuticals, INC. | $151.03 | 2022-2025 | Gvoke Hypopen |
| Esperion Therapeutics, INC. | $149.98 | 2020-2025 | Nexletol |
| Biohaven Pharmaceuticals, INC. | $143.04 | 2021 | |
| Verity Pharmaceuticals INC. | $139.39 | 2024-2025 | Tlando |
| Eisai INC. | $133.34 | 2020-2022 | |
| Endo Pharmaceuticals INC. | $130.24 | 2019-2022 | |
| Rhythm Pharmaceuticals, INC. | $129.44 | 2021-2022 | |
| Alfasigma USA, INC. | $118.12 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $116.36 | 2023-2025 | Rexulti |
| Madrigal Pharmaceuticals | $107.20 | 2024-2025 | Rezdiffra, Resmetirom |
| Idorsia Pharmaceuticals US INC | $103.11 | 2022-2024 | Quviviq |
| Exact Sciences Corporation | $90.76 | 2023-2025 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $76.10 | 2019-2020 | |
| Lexicon Pharmaceuticals, INC. | $76.08 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $66.53 | 2019-2023 | Dupixent |
| Corcept Therapeutics | $60.65 | 2023-2024 | Korlym |
| Shield Therapeutics INC | $58.33 | 2024-2025 | |
| Horizon Therapeutics Plc | $54.00 | 2020-2022 | |
| Harmony Biosciences LLC | $48.27 | 2023-2025 | Wakix |
| Arbor Pharmaceuticals, INC. | $45.29 | 2020-2021 | |
| Insulet Corporation | $43.60 | 2025 | Omnipod |
| Nalpropion Pharmaceuticals LLC | $41.74 | 2019 | |
| Halozyme INC | $40.10 | 2023 | |
| Ibsa Pharma INC. | $34.96 | 2024-2025 | Tirosint, Licart, Flector |
| Evoke Pharma, INC. | $30.20 | 2022-2023 | Gimoti |
| Genzyme Corporation | $28.40 | 2022 | |
| Inspire Medical Systems, INC. | $22.49 | 2023 | Inspire |
| Recordati_rare_diseases_inc. | $21.93 | 2025 | Isturisa |
| Kowa Pharmaceuticals America, INC. | $18.87 | 2025 | Zoryve |
| Clarus Therapeutics INC. | $17.15 | 2021 | |
| Dexcom, INC. | $16.76 | 2023 | Dexcom G6 Transmitter |
| Ironshore Pharmaceuticals INC. | $16.70 | 2023 | Jornay Pm |
| Echosens North America, INC. | $13.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yazen Joudeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.